ATC Code M01AE03, M02AA10
Formula C16H14O3
Molar Mass (g·mol−1) 254,28
Physical State solid
Melting Point (°C) 94
PKS Value 4.45
CAS Number 22071-15-4
PUB Number 3825
Drugbank ID DB01009
Solubility sparingly soluble in water


Ketoprofen belongs to the propionic acid class of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic and antipyretic effects. Ketoprofen is generally prescribed for arthritis-related inflammatory pain or severe toothache leading to inflammation of the gums. Ketoprofen in topical patches is used to treat musculoskeletal pain. Ketoprofen may also be used to treat some pain, especially nerve pain such as sciatica, post-herpetic neuralgia, and referring pain from radiculopathy, in the form of a cream, ointment, liquid, spray, or gel.



The anti-inflammatory effect of ketoprofen is thought to be due to inhibition of cyclooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever, and inflammation.


Ketoprofen is rapidly and well absorbed orally, with maximum plasma levels reached within 0.5 to 2 hours. It is 99% bound to plasma proteins, primarily albumin. It is rapidly and extensively metabolized in the liver, mainly by conjugation to glucuronic acid and by the CYP3A4 and CYP2C9 enzymes. No active metabolites have been identified. Over a 24-hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as a glucuronide metabolite. The half-life is approximately 1-4 hours.


Side Effects

Adverse effects include:

  • Nausea
  • Dyspepsia
  • Diarrhea
  • constipation
  • gastrointestinal ulceration/bleeding
  • headache
  • Dizziness
  • Skin rash
  • salt and fluid retention
  • high blood pressure

Rare adverse effects include esophageal ulcers, heart failure, high blood potassium levels, kidney dysfunction, confusion, and bronchospasm. Ketoprofen may exacerbate asthma, so use is contraindicated in asthmatics.

Toxicological Data

LD50 (rat, oral): 62.4 mg-kg-1


  • Drugbank
  • PubChem
  • Aktories, Förstermann, Hofmann, Starke: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsvier, 2017
Markus Falkenstätter

Markus Falkenstätter

Markus Falkenstätter ist Autor zu pharmazeutischen Themen in der Medizin-Redaktion von Medikamio. Er befindet sich im letzten Semester seines Pharmaziestudiums an der Universität Wien und liebt das wissenschaftliche Arbeiten im Bereich der Naturwissenschaften.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer

Stefanie Lehenauer ist seit 2020 freie Autorin bei Medikamio und studierte Pharmazie an der Universität Wien. Sie arbeitet als Apothekerin in Wien und ihre Leidenschaft sind pflanzliche Arzneimittel und deren Wirkung.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.